FrancophonIA/ELRC3.0 huggingface dataset:
English: The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysm and/or artery dissections.
Croatian: Primjena inhibitora VEGF puta u bolesnika s hipertenzijom ili bez nje može potaknuti stvaranje aneurizama i/ili disekcija arterije.
English: Potential induction of human CYP3A4 was demonstrated in an in vitro human PXR assay.
Croatian: Potencijalna indukcija ljudskog CYP3A4 pokazana je in vitro metodom „human PXR assay“.
English: Elevated blood pressure levels (systolic blood pressure ≥150 mm Hg or diastolic blood pressure ≥100 mm Hg) occurred early in the course of treatment (approximately 40% of cases occurred by day 9 and approximately 90% of cases occurred in the first 18 weeks).
Croatian: Povišene razine krvnog tlaka (sistolički tlak ≥150 mmHg ili dijastolički tlak ≥100 mmHg) javljale su se rano tijekom razdoblja liječenja (približno 40% slučajeva se javilo u prvih 9 dana i približno 90% se javilo u prvih 18 tjedana).
English: Tell your doctor or pharmacist if any of these effects become troublesome.
Croatian: Recite svom liječniku ili ljekarniku ako bilo koja od ovih nuspojava počne predstavljati problem.
English: Other observed effects include body weight loss, diarrhoea and/or morbidity that were either secondary to local gastrointestinal effects caused by high local mucosal medicinal product exposure (monkeys) or pharmacological effects (rodents).
Croatian: Drugi zabilježeni učinci uključuju gubitak tjelesne težine, proljev i/ili morbiditete koji su bili sekundarni zbog lokalnih gastrointestinalnih učinaka uzrokovanih visokom lokalnom izloženošću sluznice lijeku (u majmuna) ili farmakološkim učincima (u glodavaca).
English: Votrient can cause separation or tear of the lining of the back part of the eye (retinal detachment or tear).
Croatian: Votrient može uzrokovati odvajanje ili razdor ovojnice na stražnjem dijelu oka (odvajanje ili razdor mrežnice).
English: Post-marketing data on safety and tolerability across all pazopanib clinical studies and from spontaneous reports have also been evaluated.
Croatian: Nakon stavljanja lijeka u promet bili su također procijenjeni podaci o sigurnosti i podnošljivosti iz svih kliničkih ispitivanja s pazopanibom i iz spontanih prijava.
English: Interruption of pazopanib and/or dose reduction should be combined with treatment of hypertension (if present, refer to hypertension warning section above) in patients with significant reductions in LVEF, as clinically indicated.
Croatian: Prekid liječenja pazopanibom i/ili smanjenje doze treba kombinirati s liječenjem hipertenzije (ukoliko je prisutna, pogledati upozorenje za hipertenziju u prethodnom dijelu teksta) u bolesnika sa značajnim smanjenjem LVEF-a, prema kliničkoj indikaciji.
English: The median duration of follow-up of subjects (defined as date of randomisation to date of last contact or death) was similar for both treatment arms (9.36 months for placebo [range 0.69 to 23.0 months] and 10.04 months for pazopanib [range 0.2 to 24.3 months].
Croatian: Srednje vrijeme praćenja ispitanika (definirano kao vrijeme od randomizacije do posljednjeg kontakta ili smrti) bilo je slično za oba ispitivana kraka (9,36 mjeseci za placebo [raspon 0,69 do 23,0 mjeseci] i 10,04 za pazopanib [raspon 0,2 do 24,3 mjeseci].
English: In addition, concomitant use of pazopanib and other statins should be undertaken with caution as there are insufficient data available to assess their impact on ALT levels.
Croatian: Nadalje, potreban je oprez pri istodobnoj primjeni pazopaniba i drugih statina jer su nedostatni podaci kojima se procjenjuje njihov utjecaj na razine ALT-a.
English: Votrient can cause a tear (perforation) in your stomach or intestinal wall or the development of an abnormal connection between two parts of your digestive tract (a fistula).
Croatian: Votrient može uzrokovati razdor (proboj) u Vašem želucu ili crijevnom zidu ili razvoj neuobičajenih spojeva između dva dijela Vašeg probavnog trakta (fistula).
English: Do not break or crush the tablets as this affects the way the medicine is absorbed and may increase the chance of side effects.
Croatian: Nemojte lomiti ili mrviti tablete jer to utječe na način apsorpcije lijeka te može povećati mogućnost pojave nuspojava.
English: When post-weaning rats were dosed from day 21 post partum to day 62 post partum, toxicological findings were similar to adult rats at comparable exposures.
Croatian: Kada su štakori dozirani od 21. do 62. dana nakon rođenja, toksikološki nalazi bili su slični onima u odraslih štakora pri sličnoj izloženosti.
English: Median (months) Response rate
Croatian: Medijan (mjeseci) Stopa odgovora
English: Swelling of the brain (reversible posterior leukoencephalopathy syndrome) Votrient can, on rare occasions, cause swelling of the brain, which may be life threatening.
Croatian: Oticanje mozga (sindrom reverzibilne posteriorne leukoencefalopatije) Votrient u rijetkim slučajevima može uzrokovati oticanje mozga, koje može biti opasno po život.
English: Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG12 0DJ, United Kingdom.
Croatian: Glaxo Operations UK Ltd (posluje kao Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG120DJ, Ujedinjeno Kraljevstvo
English: Stop taking Votrient and seek medical help immediately if you get any of these symptoms, or if you get headache accompanied with any of these symptoms.
Croatian: Prestanite uzimati Votrient i odmah potražite liječničku pomoć u slučaju pojave bilo kojega od navedenih simptoma ili glavobolje praćene nekim od tih simptoma.
English: Soft-tissue sarcoma (STS)
Croatian: Sarkom mekih tkiva (STS)
English: Blood pressure should be monitored and managed promptly using a combination of anti-hypertensive therapy and dose modification of pazopanib (interruption and re-initiation at a reduced dose based on clinical judgement) (see sections 4.2 and 4.8).
Croatian: Krvni tlak treba kontrolirati te brzo korigirati primjenom antihipertenzivne terapije i modifikacijom doze pazopaniba (prekid i ponovni početak liječenja smanjenom dozom na temelju kliničke procjene) (vidjeti dijelove 4.2 i 4.8).
English: The active metabolite of irinotecan, SN-38, is a substrate for OATP1B1 and UGT1A1.
Croatian: Aktivni metabolit irinotekana, SN-38, supstrat je za OATP1B1 i UGT1A1.
English: It should be taken without food, at least one hour before or two hours after a meal (see section 5.2).
Croatian: Treba se uzimati bez hrane, barem jedan sat prije ili dva sata nakon obroka (vidjeti dio 5.2).
English: PFS Overall ITT
Croatian: PFS Sveukupna ITT
English: HR = hazard ratio; ITT = intent to treat; PFS = progression-free survival; CR = complete response; PR = partial response.
Croatian: HR = omjer hazarda; ITT = namjera liječenja; PFS = preživljenje bez progresije; CR = potpuni odgovor; PR = djelomični odgovor.
English: Sixty-six per cent of placebo patients received post-study therapy compared to 30% of pazopanib patients.
Croatian: Šezdeset šest posto bolesnika iz placebo skupine je primalo terapiju nakon ispitivanja u usporedbi s 30% bolesnika iz pazopanib skupine.
English: If the potential benefit of reinitiating pazopanib treatment is considered to outweigh the risk for hepatotoxicity, then reintroduce pazopanib at a reduced dose of 400 mg daily and perform serum liver tests weekly for 8 weeks.
Croatian: Ako se smatra da je moguća korist od ponovnog uvođenja pazopaniba veća od rizika od hepatotoksičnosti, pazopanib treba ponovno uvesti u smanjenoj dozi od 400 mg na dan te provjeriti jetrene enzime u serumu svakog tjedna tijekom 8 tjedana.
English: Since vascular endothelial growth factor (VEGF) inhibitors may impair wound healing, treatment with pazopanib should be stopped at least 7 days prior to scheduled surgery.
Croatian: Kako inhibitori vaskularnog endotelnog čimbenika rasta (VEGF; engl. vascular endothelial growth factor) mogu negativno utjecati na cijeljenje rana, terapiju pazopanibom treba obustaviti barem 7 dana prije predviđenog operacijskog zahvata.
English: Adults The recommended dose of pazopanib for the treatment of RCC or STS is 800 mg once daily.
Croatian: Odrasli Preporučena doza pazopaniba za liječenje RCC-a ili STS-a je 800 mg jednom dnevno.
English: - The other ingredients in the 200 mg and 400 mg tablets are: hypromellose, macrogol 400, magnesium stearate, microcrystalline cellulose, polysorbate 80, povidone (K30), sodium starch glycolate, titanium dioxide (E171).
Croatian: - Drugi sastojci u tabletama od 200 i 400 mg su: hipromeloza, makrogol 400, magnezijev stearat, mikrokristalična celuloza, polisorbat 80, povidon (K30), natrijev škroboglikolat, titanijev dioksid (E171).
English: It cannot be excluded that pazopanib will affect the pharmacokinetics of substrates of OATP1B1 (e.g. statins, see “Effect of concomitant use of pazopanib and simvastatin” below).
Croatian: Ne može se isključiti mogućnost da pazopanib utječe na farmakokinetiku OATP1B1 supstrata (npr. statini, vidjeti ispod „Učinak istodobne uporabe pazopaniba i simvastatina“).
English: Patients over 60 years of age may be at greater risk for mild (>3 x ULN) to severe (>8 x ULN) elevation of ALT.
Croatian: Bolesnici stariji od 60 godina mogu biti pod većim rizikom od blagog (>3 x GGN) do teškog (>8 x GGN) povećanja ALT-a.
English: The usual dose is two Votrient 400 mg tablets (800 mg pazopanib) taken once a day.
Croatian: Uobičajena doza je dvije Votrient 400 mg tablete (800 mg pazopaniba) uzete jednom dnevno.
English: Infections occurring while you take Votrient may possibly become serious.
Croatian: Postoji mogućnost da infekcije koje se jave za vrijeme uzimanja lijeka Votrient postanu ozbiljne.
English: The primary objective of the study was progression-free survival (PFS assessed by independent radiological review); the secondary endpoints included overall survival (OS), overall response rate and duration of response.
Croatian: Primarni cilj ovog ispitivanja bilo je vrijeme bez progresije bolesti (PFS ocijenjeno od strane neovisnog radiološkog pregleda); sekundarne mjere ishoda uključivale su sveukupno preživljenje (OS), sveukupnu stopu odgovora i trajanje odgovora.
English: Posterior reversible encephalopathy syndrome (PRES)/Reversible posterior leukoencephalopathy syndrome (RPLS)
Croatian: Sindrom reverzibilne posteriorne encefalopatije (PRES)/Sindrom reverzibilne posteriorne leukoencefalopatije (RPLS)
English: The performance status (ECOG) was similar between the pazopanib and placebo groups (ECOG 0: 42% vs. 41%, ECOG 1: 58% vs. 59%).
Croatian: ECOG status je bio sličan između grupa s pazopanibom i placebom (ECOG 0: 42% u odnosu na 41%, ECOG 1: 58% u odnosu na 59%).
English: The safety and pharmacokinetics of pazopanib in patients with moderate to severe heart failure or those with a below normal left ventricular ejection fraction (LVEF) have not been studied.
Croatian: Sigurnost i farmakokinetika pazopaniba u bolesnika s umjerenim do teškim zatajenjem srca ili u onih s ejekcijskom frakcijom lijeve klijetke (LVEF) ispod normale nisu ispitivane.
English: Gastrointestinal (GI) perforations and fistula
Croatian: Gastrointestinalne (GI) perforacije i fistule
English: In vitro, pazopanib inhibited human organic anion transporting polypeptide (OATP1B1).
Croatian: In vitro, pazopanib je inhibirao humani organski anionski transportni polipeptid (OATP1B1).
English: Votrient can, on rare occasions, cause lung inflammation (interstitial lung disease, pneumonitis), which in some people can be fatal.
Croatian: U rijetkim slučajevima Votrient može uzrokovati upalu pluća (intersticijsku bolest pluća, pneumonitis), koja u nekih osoba može imati smrtni ishod.
English: ‘Other STS' subgroups
Croatian: „Ostale STS“ podgrupe
English: Furthermore, inhibition of BCRP and P-gp by pazopanib in the gastrointestinal tract cannot be excluded.
Croatian: Nadalje, ne može se isključiti inhibicija BCRP-a i P-gp-a od strane pazopaniba u gastrointestinalnom traktu.
English: Rare side effects (may affect up to 1 in 1,000 people): - inflammation of the lung (pneumonitis)
Croatian: Rijetke nuspojave (mogu se javiti kod manje od 1 na 1000 ljudi): - upala pluća (pneumonitis)
English: There are no adequate data from the use of pazopanib in pregnant women.
Croatian: Ne postoje adekvatni podaci o primjeni pazopaniba u trudnica.
English: Effects included reduced female fertility, increased pre- and post-implantation loss, early resorptions, embryo lethality, decreased foetal body weight and cardiovascular malformation.
Croatian: Učinci su uključivali smanjenje ženske plodnosti, povećan gubitak ploda u pre- i postimplantacijskom razdoblju, ranu resorpciju, letalitet embrija, smanjenje fetalne tjelesne mase i kardiovaskularne malformacije.
English: †Treatment-related adverse reaction reported during post-marketing period (spontaneous case reports and serious adverse reactions from all pazopanib clinical studies).
Croatian: †Nuspojave povezane s liječenjem prijavljene nakon stavljanja lijeka u promet (spontane prijave i ozbiljne nuspojave iz svih kliničkih ispitivanja s pazopanibom).
English: Outcome
Croatian: Ishod
English: In a Phase II study of 225 patients with locally recurrent or metastatic clear cell renal cell carcinoma, objective response rate was 35% and median duration of response was 68 weeks, as per independent review.
Croatian: Prema neovisnoj procjeni, u ispitivanju faze II u 225 bolesnika s lokalno recidivirajućim ili metastazirajućim karcinomom bubrega svijetlih stanica, objektivna stopa odgovora bila je 35%, a medijan trajanja odgovora bio je 68 tjedana.
English: g Cardiac dysfunction events - includes Left ventricular dysfunction, Cardiac failure and Restrictive cardiomyopathy h Frequency is based on adverse events reported by investigators.
Croatian: g Slučajevi disfunkcije srca - uključujući disfunkciju lijevog ventrikula, zatajenje srca i restriktivnu kardiomiopatiju h Učestalost se temelji na nuspojavama koje su prijavili ispitivači.
English: Clinical studies of pazopanib in combination with pemetrexed (non-small cell lung cancer [NSCLC]) and lapatinib (cervical cancer) were terminated early due to concerns over increased toxicity and/or mortality, and a safe and effective combination dose has not been established with these regimens.
Croatian: Klinička ispitivanja pazopaniba u kombinaciji s pemetreksedom (rak pluća nemalih stanica [NSCLC]) i lapatinibom (karcinom vrata maternice) su prekinuta ranije uslijed zabrinutosti zbog povećane toksičnosti i/ili smrtnosti, te sigurna i učinkovita kombinacija doza nije ustanovljena za ove režime liječenja.
English: In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in various animal models, and the growth of multiple human tumour xenografts in mice.
Croatian: In vivo, pazopanib je u plućima miša inhibirao VEGF-induciranu VEGFR-2 fosforilaciju, angiogenezu u različitim životinjskim modelima i rast multiplih ljudskih tumorskih ksenograftova u miševa.
English: Votrient can affect heart rhythm which in some people can develop into a potentially serious heart condition known as torsade de pointes.
Croatian: Promjene srčanog ritma (produljenje QT intervala) Votrient može utjecati na srčani ritam, što se kod nekih ljudi može razviti u potencijalno ozbiljno stanje srca poznato kao torsade de pointes.
English: Votrient can cause problems with your liver which may develop into serious conditions such as liver dysfunction and liver failure, which may be fatal.
Croatian: Votrient može uzrokovati probleme s Vašom jetrom koji se mogu razviti u ozbiljno stanje kao što je poremećaj funkcije jetre i zatajenje jetre, koje može imati smrtni ishod.
English: Male patients (including those who have had vasectomies) should use condoms during sexual intercourse while taking pazopanib and for at least 2 weeks after the last dose of pazopanib to avoid potential exposure to the medicinal product for pregnant partners and female partners of reproductive potential.
Croatian: Muški bolesnici (uključujući one koji su imali vazektomiju) trebaju koristiti prezervative tijekom spolnog odnosa dok uzimaju pazopanib i najmanje 2 tjedna nakon posljednje doze pazopaniba kako bi se izbjegla potencijalna izloženost lijeku trudnih partnerica ili ženskih partnerica reproduktivnog potencijala.
English: In clinical studies with pazopanib, events of hypertension including newly diagnosed symptomatic episodes of elevated blood pressure (hypertensive crisis) have occurred.
Croatian: Tijekom kliničkih ispitivanja pazopaniba zabilježeni su slučajevi hipertenzije, uključujući novodijagnosticirane simptomatske epizode povišenog krvnog tlaka (hipertenzivna kriza).
English: It is not known whether the ingredients in Votrient pass into breast milk.
Croatian: Nije poznato prelaze li sastojci lijeka Votrient u mlijeko.
English: The effect of Votrient during pregnancy is not known.
Croatian: Nije poznat utjecaj lijeka Votrient tijekom trudnoće.
English: Votrient treatment should only be initiated by a physician experienced in the administration of anti-cancer medicinal products.
Croatian: Terapiju lijekom Votrient smije započeti samo liječnik koji ima iskustva u primjeni antitumorskih lijekova.
English: It cannot be excluded that pazopanib will affect the pharmacokinetics of other statins (e.g. atorvastatin, fluvastatin, pravastatin, rosuvastatin).
Croatian: Ne može se isključiti da pazopanib može utjecati na farmakokinetiku drugih statina (npr. atorvastatin, fluvastatin, pravastatin, rosuvastatin).
English: Pazopanib has been shown to be embryotoxic and teratogenic when administered to rats and rabbits at exposures more than 300-fold lower than the human exposure (based on AUC).
Croatian: Pokazano je da je pazopanib embriotoksičan i teratogen u štakora i zečeva pri izloženosti koja je više od 300 puta manja od ljudske izloženosti (temeljem AUC-a).
English: In such cases there should be close attention to adverse drug reaction, and further dose reduction may be considered if possible drug-related adverse events are observed.
Croatian: U takvim slučajevima treba pomno pratiti nuspojave te ukoliko se zabilježe nuspojave moguće povezane s lijekom razmisliti o daljnjem smanjenju doze.
English: Votrient can have side effects that may affect your ability to drive or use machines.
Croatian: Votrient može uzrokovati nuspojave koje mogu utjecati na Vašu sposobnost upravljanja vozilom ili korištenja strojeva.
English: Pazopanib is a UGT1A1 inhibitor.
Croatian: Pazopanib je inhibitor UGT1A1.
English: It is not known whether pazopanib or its metabolites are excreted in human milk.
Croatian: Nije poznato izlučuje li se pazopanib ili njegovi metaboliti u majčino mlijeko u ljudi.
English: The safety and efficacy of pazopanib in RCC were evaluated in a randomised, double-blind, placebo-controlled multicentre study.
Croatian: Sigurnost primjene i djelotvornost pazopaniba u RCC-u procjenjivani su u randomiziranom, dvostruko slijepom, multicentričnom ispitivanju koje je bilo kontrolirano placebom.
English: It can occur in muscles, blood vessels, fat tissue or other tissues that support,
Croatian: Može se pojaviti u mišićima, krvnim žilama, masnom tkivu ili drugim tkivima koja potpomažu, okružuju i štite organe.
English: Votrient may cause blood clots in the small blood vessels in the kidneys and brain accompanied by a decrease in red blood cells and cells involved in clotting (thrombotic microangiopathy, TMA).
Croatian: Votrient može uzrokovati krvne ugruške u malim krvnim žilama u bubrezima i mozgu koji su praćeni smanjenim brojem crvenih krvnih stanica i stanica uključenih u zgrušavanje krvi (trombotička mikroangiopatija, TMA).
English: Do not use this medicine after the expiry date (EXP) which is stated on the bottle and the carton.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na boci i na kutiji iza oznake „EXP“.
English: There are no animal data on the excretion of pazopanib in animal milk.
Croatian: Ne postoje podaci o izlučivanju pazopaniba u životinjskom mlijeku.
English: Patients were stratified by the factors of WHO performance status (WHO PS) (0 or 1) at baseline and the number of lines of prior systemic therapy for advanced disease (0 or 1 vs. 2+).
Croatian: Bolesnici su stratificirani prema „performance status“ SZO kriterijima (WHO PS) (0 ili 1) na početku ispitivanja i po broju prethodnih linija sistemske terapije za uznapredovalu bolest (0 ili 1 naspram 2+).
English: Following reintroduction of pazopanib, if transaminase elevations >3 x ULN recur, then pazopanib should be permanently discontinued.
Croatian: Ako nakon ponovnog uvođenja pazopaniba ponovno dođe do porasta transaminaza na >3 x GGN, treba trajno prekinuti liječenje pazopanibom.
English: Of note, patients with adipocytic sarcoma were excluded from the pivotal Phase III study as in a preliminary Phase II study (VEG20002) activity (PFS at week 12) observed with pazopanib in adipocytic did not meet the prerequisite rate to allow further clinical testing.
Croatian: Uz to, bolesnici s adipocitnim sarkomom bili su izostavljeni iz ključnog ispitivanja faze III, kao i iz preliminarnog ispitivanja faze II (VEG20002), zabilježena aktivnost pazopaniba u adipocitnom sarkomu (PFS u 12. tjednu) nije dosegla prethodno zadanu stopu da bi dopustila daljnje kliničko ispitivanje.
English: Combination with strong P-gp or BCRP inhibitors should be avoided, or selection of an alternate concomitant medicinal product with no or minimal potential to inhibit P-gp or BCRP is recommended.
Croatian: Treba izbjegavati kombiniranje s jakim inhibitorima P-gp-a ili BCRP-a, ili se preporučuje odabir istodobne alternativne terapije lijekovima koji ne inhibiraju ili imaju minimalni potencijal za inhibiciju P-gp-a ili BCRP-a.
English: No significant difference in OS was observed between the two treatment arms at the final OS analysis performed after 76% (280/369) of the events had occurred (HR 0.87, 95% CI 0.67, 1.12 p=0.256).
Croatian: Nije zabilježena značajna razlika u OS-u između dva kraka ispitivanja u završnoj analizi ukupnog preživljenja izvedenoj nakon što je zabilježeno 76% (280/389) događaja (HR 0,87; 95% CI 0,67; 1,12 p=0,256).
English: Systemic exposure to pazopanib is increased when administered with food.
Croatian: Sistemska izloženost pazopanibu se povećava pri uzimanju s hranom.
English: Your doctor will be checking your liver enzymes while you are taking Votrient.
Croatian: Vaš liječnik će provjeravati Vaše jetrene enzime za vrijeme uzimanja lijeka Votrient.
English: A similar improvement in PFS based on investigator assessments was observed in the pazopanib arm compared with the placebo arm (in the overall ITT population HR: 0.39; 95% CI, 0.30 to 0.52, p <0.001).
Croatian: Slično poboljšanje u PFS-u na temelju procjene ispitivača zabilježeno je u kraku s pazopanibom u usporedbi s placebo krakom (u sveukupnoj ITT populaciji HR: 0,39; 95% CI, 0,30 do 0,52; p <0,001).
English: Human paediatric patients are at increased risk for bone and teeth effects as compared to adults, as these changes, including inhibition of growth (shortened limbs), fragile bones and remodelling of teeth, were present in juvenile rats at ≥10 mg/kg/day (equal to approximately 0.1-0.2 times the clinical exposure based on AUC in adult humans) (see section 4.4).
Croatian: Djeca su u povećanom riziku za učinak na kost i zube u usporedbi s odraslim ljudima, jer su ove promjene, uključujući inhibiciju rasta (skraćeni udovi), krhke kosti i remodeliranje zuba, bile prisutne u mladih štakora pri ≥10 mg/kg/dan (jednako kao približno 0,1-0,2 puta kliničke izloženosti na temelju AUC-a u odraslih ljudi) (vidjeti dio 4.4).
English: Co-administration of pazopanib with other strong inhibitors of the CYP3A4 family (e.g. itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase pazopanib concentrations.
Croatian: Istovremena primjena pazopaniba s drugim jakim inhibitorima obitelji CYP3A4 (npr. itrakonazol, klaritromicin, atazanavir, indinavir, nefazodon, nelfinavir, ritonavir, sakvinavir, telitromicin, vorikonazol) može povećati koncentracije pazopaniba.